Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.

Luc ManlayGilles BoschettiBruno PereiraBernard FlouriéMichel DapoignyMaud ReymondElisa SollelisClaire GayMathilde BoubeAnthony BuissonStéphane Nancey

Published in: Alimentary pharmacology & therapeutics (2021)

Ustekinumab was more effective to achieve early and long-term effectiveness than vedolizumab in Crohn's disease patients who previously failed response to anti-TNF agents.

Keyphrases

randomized controlled trial
systematic review
ulcerative colitis
rheumatoid arthritis
patients with inflammatory bowel disease
stem cells
mesenchymal stem cells